GSK reported sales from Covid-19 “solutions” of £276 million in the first half of the yearSales of a booster for Covid-19 vaccines have helped to lift quarterly sales at GlaxoSmithKline ahead of City forecasts. For the first time, the drugs group yesterday disclosed sales from its Covid-19 “solutions”, showing £276 million in the first half of the year, of which £258 million comprised adjuvant sales to partner drugs companies and £16 million from sotrovimab, its investigational monoclonal antibody therapy for the treatment of coronavirus patients with mild symptoms. SponsoredEarlier GSK said that it had signed a contract with the European Union for the supply of sotrovimab, which has emergency use authorisation in the EU and the United States. The sales helped to offset pressures elsewhere in the group’s vaccines business, one of its three divisions, which has been disrupted by

Source: The Times July 28, 2021 14:03 UTC